Skip to main content

Advertisement

SpringerLink
Log in

Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Objectives

To assess the potential efficacy of the effects of neoadjuvant hormonal therapy on high-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer.

Methods

One hundred seventy patients with localized prostate cancer underwent HIFU of the prostate, of which 114 patients, who met the study criteria, were included in the current study. The primary outcome was prostate-specific antigen (PSA) changes, and the secondary outcome was morbidity. Biochemical failure was defined according to the Phoenix criteria (prostate-specific antigen nadir +2 ng/ml).

Results

The median follow-up period for all patients was 45.0 months (range: 12–70). All patients underwent PSA evaluation, and 52 (56.5%) had a 2-month PSA nadir recorded at the follow-up visit. PSA nadir was achieved by 3 months in 84.2% of treatments. The mean PSA nadir was 0.28 ng/ml. The 114 patients consisted of two groups: 44 patients treated with neoadjuvant hormonal therapy (group 1), and 70 patients treated without neoadjuvant hormonal therapy (group 2). The mean PSA nadir achieved in group 1 was 0.19 ng/ml versus 0.34 ng/ml in group 2 (n.s.). The occurrence rates of treatment-related toxicities were similar in both groups.

Conclusion

In patients with localized prostate cancer, HIFU therapy resulted in comparable immediate cancer control. The present results indicate that combined treatment using hormonal therapy and HIFU does not have a synergistic effect on the PSA nadir.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974

    Article  PubMed  Google Scholar 

  2. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the rtog-astro phoenix consensus conference. Int J Radiat Oncol Biol Phys 65(4):965–974. doi:10.1016/j.ijrobp.2006.04.029

    Article  PubMed  Google Scholar 

  3. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR (2003) National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95(13):981–989

    Article  PubMed  Google Scholar 

  4. Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, Eley JW, Liff JM, Deapen D, Stephenson RA, Legler J, Ferrans CE, Talcott JA, Litwin MS (1999) Prostate cancer practice patterns and quality of life: the prostate cancer outcomes study. J Natl Cancer Inst 91(20):1719–1724

    Article  PubMed  CAS  Google Scholar 

  5. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341(24):1781–1788

    Article  PubMed  CAS  Google Scholar 

  6. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K (2002) Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 90(6):561–566

    Article  PubMed  CAS  Google Scholar 

  7. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–164. doi:10.1056/NEJMoa041943

    Article  PubMed  CAS  Google Scholar 

  8. Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39–46. doi:10.1093/jnci/djp404

    Article  PubMed  CAS  Google Scholar 

  9. Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE (2009) Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 55(1):62–75. doi:10.1016/j.eururo.2008.10.008

    Article  PubMed  Google Scholar 

  10. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR (2009) Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: Rtog 85–31. J Clin Oncol 27(1):92–99. doi:10.1200/JCO.2007.12.3752

    Article  PubMed  Google Scholar 

  11. Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A (2008) First analysis of the long-term results with transrectal hifu in patients with localised prostate cancer. Eur Urol 53(6):1194–1201. doi:10.1016/j.eururo.2007.10.062

    Article  PubMed  Google Scholar 

  12. Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF, Blana A (2008) Psa nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (hifu) treatment of localised prostate cancer. Eur Urol 53(3):547–553. doi:10.1016/j.eururo.2007.07.010

    Article  PubMed  CAS  Google Scholar 

  13. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A (2006) Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 97(1):56–61. doi:10.1111/j.1464-410X.2006.05864.x

    Article  PubMed  Google Scholar 

  14. Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B (2006) Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 24(5):585–590. doi:10.1007/s00345-006-0107-x

    Article  PubMed  Google Scholar 

  15. Chaussy C, Thuroff S (2003) The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 4(3):248–252

    Article  PubMed  Google Scholar 

  16. Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A (2007) Control of prostate cancer by transrectal hifu in 227 patients. Eur Urol 51(2):381–387. doi:10.1016/j.eururo.2006.04.012

    Article  PubMed  CAS  Google Scholar 

  17. Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, Scott R, Calleary J, Illing R, Kirkham A, Freeman A, Ogden C, Allen C, Emberton M (2009) High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first uk series. Br J Cancer 101(1):19–26. doi:10.1038/sj.bjc.6605116

    Article  PubMed  CAS  Google Scholar 

  18. Shoji S, Nakano M, Nagata Y, Usui Y, Terachi T, Uchida T (2010) Quality of life following high-intensity focused ultrasound for the treatment of localized prostate cancer: a prospective study. Int J Urol 17(8):715–719. doi:10.1111/j.1442-2042.2010.02568.x

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan

    Yutaka Fujisue, Haruhito Azuma, Teruo Inamoto, Kazumasa Komura, Hiroshi Masuda & Yoji Katsuoaka

  2. Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA

    Piyush K. Agarwal

  3. Department of Urology, Hirakata City Hospital, Hirakata, Osaka, Japan

    Toshikazu Watsuji

Authors
  1. Yutaka Fujisue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haruhito Azuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Teruo Inamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazumasa Komura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Piyush K. Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Masuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toshikazu Watsuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoji Katsuoaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Teruo Inamoto.

Additional information

Yutaka Fujisue, Haruhito Azuma, and Teruo Inamoto equally attributed to the work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fujisue, Y., Azuma, H., Inamoto, T. et al. Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer. World J Urol 29, 689–694 (2011). https://doi.org/10.1007/s00345-010-0628-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-010-0628-1

Keywords

Search

Navigation